APO Research
Talk to an analyst

APO RESEARCH · REPORT

Repurposed Drugs

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Repurposed Drugs Market Analysis and Forecast 2026-2032

2 January 2026198 pages

Choose your research edition.

Industry ResearchRepurposed Drugs Industry Research Report 2026120 pages · $2,950 USDIndustry Growth & TrendsGlobal Repurposed Drugs Industry Growth and Trends Forecast to 2032104 pages · $3,450 USDMarket StructureGlobal Repurposed Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032192 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Repurposed Drugs Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Repurposed Drugs Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

The global Repurposed Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Repurposed Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Repurposed Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Repurposed Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Repurposed Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Repurposed Drugs include Teva, Johnson & Johnson, Novartis, Mylan, Pfizer, GSK, R-Pharma, Glenmark and Fujifilm, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Repurposed Drugs, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Repurposed Drugs, also provides the revenue of main regions and countries. Of the upcoming market potential for Repurposed Drugs, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Repurposed Drugs revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Repurposed Drugs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Repurposed Drugs revenue, projected growth trends, production technology, application and end-user industry.

Repurposed Drugs Segment by Company

Teva

Johnson & Johnson

Novartis

Mylan

Pfizer

GSK

R-Pharma

Glenmark

Fujifilm

Dr. Reddy

ChemRar Group

Bausch Health

Repurposed Drugs Segment by Type

Generic Drugs

Clinical Trial Failed Drugs

Repurposed Drugs Segment by Application

Cardiovascular Diseases

Mental Illness

Cancer

Other

Repurposed Drugs Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Repurposed Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Repurposed Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Repurposed Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Repurposed Drugs in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Repurposed Drugs company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Repurposed Drugs revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Repurposed Drugs Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Generic Drugs Major Player Table 3. Clinical Trial Failed Drugs Major Player Table 4. Global Repurposed Drugs Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Cardiovascular Diseases Major Player Table 6. Mental Illness Major Player Table 7. Cancer Major Player Table 8. Other Major Player Table 9. Repurposed Drugs Industry Trends Table 10. Repurposed Drugs Industry Drivers Table 11. Repurposed Drugs Industry Opportunities and Challenges Table 12. Repurposed Drugs Industry Restraints Table 13. Global Repurposed Drugs Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 14. Global Repurposed Drugs Market Size by Region (2021-2026) & (US$ Million) Table 15. Global Repurposed Drugs Market Share by Region (2021-2026) Table 16. Global Repurposed Drugs Market Size by Region (2027-2032) & (US$ Million) Table 17. Global Repurposed Drugs Market Share by Region (2027-2032) Table 18. Global Repurposed Drugs Revenue by Players (US$ Million) & (2021-2026) Table 19. Global Repurposed Drugs Revenue Market Share by Players (2021-2026) Table 20. Global Repurposed Drugs Key Players Ranking, 2024 VS 2025 VS 2026 Table 21. Global Repurposed Drugs Key Players Headquarters & Area Served Table 22. Global Repurposed Drugs Players, Product Type & Application Table 23. Global Repurposed Drugs Players Establishment Date Table 24. Global Players Market Concentration Ratio (CR5 and HHI) Table 25. Global Repurposed Drugs by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 26. Global Repurposed Drugs Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Repurposed Drugs Revenue by Type (2021-2026) & (US$ Million) Table 28. Global Repurposed Drugs Revenue by Type (2027-2032) & (US$ Million) Table 29. Global Repurposed Drugs Revenue Market Share by Type (2021-2026) Table 30. Global Repurposed Drugs Revenue Market Share by Type (2027-2032) Table 31. Global Repurposed Drugs Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Repurposed Drugs Revenue by Application (2021-2026) & (US$ Million) Table 33. Global Repurposed Drugs Revenue by Application (2027-2032) & (US$ Million) Table 34. Global Repurposed Drugs Revenue Market Share by Application (2021-2026) Table 35. Global Repurposed Drugs Revenue Market Share by Application (2027-2032) Table 36. Teva Company Information Table 37. Teva Business Overview Table 38. Teva Repurposed Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 39. Teva Repurposed Drugs Product Portfolio Table 40. Teva Recent Development Table 41. Johnson & Johnson Company Information Table 42. Johnson & Johnson Business Overview Table 43. Johnson & Johnson Repurposed Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 44. Johnson & Johnson Repurposed Drugs Product Portfolio Table 45. Johnson & Johnson Recent Development Table 46. Novartis Company Information Table 47. Novartis Business Overview Table 48. Novartis Repurposed Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 49. Novartis Repurposed Drugs Product Portfolio Table 50. Novartis Recent Development Table 51. Mylan Company Information Table 52. Mylan Business Overview Table 53. Mylan Repurposed Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 54. Mylan Repurposed Drugs Product Portfolio Table 55. Mylan Recent Development Table 56. Pfizer Company Information Table 57. Pfizer Business Overview Table 58. Pfizer Repurposed Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 59. Pfizer Repurposed Drugs Product Portfolio Table 60. Pfizer Recent Development Table 61. GSK Company Information Table 62. GSK Business Overview Table 63. GSK Repurposed Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 64. GSK Repurposed Drugs Product Portfolio Table 65. GSK Recent Development Table 66. R-Pharma Company Information Table 67. R-Pharma Business Overview Table 68. R-Pharma Repurposed Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 69. R-Pharma Repurposed Drugs Product Portfolio Table 70. R-Pharma Recent Development Table 71. Glenmark Company Information Table 72. Glenmark Business Overview Table 73. Glenmark Repurposed Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 74. Glenmark Repurposed Drugs Product Portfolio Table 75. Glenmark Recent Development Table 76. Fujifilm Company Information Table 77. Fujifilm Business Overview Table 78. Fujifilm Repurposed Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 79. Fujifilm Repurposed Drugs Product Portfolio Table 80. Fujifilm Recent Development Table 81. Dr. Reddy Company Information Table 82. Dr. Reddy Business Overview Table 83. Dr. Reddy Repurposed Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 84. Dr. Reddy Repurposed Drugs Product Portfolio Table 85. Dr. Reddy Recent Development Table 86. ChemRar Group Company Information Table 87. ChemRar Group Business Overview Table 88. ChemRar Group Repurposed Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 89. ChemRar Group Repurposed Drugs Product Portfolio Table 90. ChemRar Group Recent Development Table 91. Bausch Health Company Information Table 92. Bausch Health Business Overview Table 93. Bausch Health Repurposed Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. Bausch Health Repurposed Drugs Product Portfolio Table 95. Bausch Health Recent Development Table 96. North America Repurposed Drugs Revenue by Type (2021-2026) & (US$ Million) Table 97. North America Repurposed Drugs Revenue by Type (2027-2032) & (US$ Million) Table 98. North America Repurposed Drugs Revenue by Application (2021-2026) & (US$ Million) Table 99. North America Repurposed Drugs Revenue by Application (2027-2032) & (US$ Million) Table 100. North America Repurposed Drugs Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 101. North America Repurposed Drugs Revenue by Country (2021-2026) & (US$ Million) Table 102. North America Repurposed Drugs Revenue by Country (US$ Million) & (2027-2032) Table 103. Europe Repurposed Drugs Revenue by Type (2021-2026) & (US$ Million) Table 104. Europe Repurposed Drugs Revenue by Type (2027-2032) & (US$ Million) Table 105. Europe Repurposed Drugs Revenue by Application (2021-2026) & (US$ Million) Table 106. Europe Repurposed Drugs Revenue by Application (2027-2032) & (US$ Million) Table 107. Europe Repurposed Drugs Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 108. Europe Repurposed Drugs Revenue by Country (2021-2026) & (US$ Million) Table 109. Europe Repurposed Drugs Revenue by Country (US$ Million) & (2027-2032) Table 110. China Repurposed Drugs Revenue by Type (2021-2026) & (US$ Million) Table 111. China Repurposed Drugs Revenue by Type (2027-2032) & (US$ Million) Table 112. China Repurposed Drugs Revenue by Application (2021-2026) & (US$ Million) Table 113. China Repurposed Drugs Revenue by Application (2027-2032) & (US$ Million) Table 114. Asia Repurposed Drugs Revenue by Type (2021-2026) & (US$ Million) Table 115. Asia Repurposed Drugs Revenue by Type (2027-2032) & (US$ Million) Table 116. Asia Repurposed Drugs Revenue by Application (2021-2026) & (US$ Million) Table 117. Asia Repurposed Drugs Revenue by Application (2027-2032) & (US$ Million) Table 118. Asia Repurposed Drugs Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 119. Asia Repurposed Drugs Revenue by Region (US$ Million) & (2021-2026) Table 120. Asia Repurposed Drugs Revenue by Region (US$ Million) & (2027-2032) Table 121. SAMEA Repurposed Drugs Revenue by Type (2021-2026) & (US$ Million) Table 122. SAMEA Repurposed Drugs Revenue by Type (2027-2032) & (US$ Million) Table 123. SAMEA Repurposed Drugs Revenue by Application (2021-2026) & (US$ Million) Table 124. SAMEA Repurposed Drugs Revenue by Application (2027-2032) & (US$ Million) Table 125. SAMEA Repurposed Drugs Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 126. SAMEA Repurposed Drugs Revenue by Country (2021-2026) & (US$ Million) Table 127. SAMEA Repurposed Drugs Revenue by Country (US$ Million) & (2027-2032) Table 128. Research Programs/Design for This Report Table 129. Authors List of This Report Table 130. Secondary Sources Table 131. Primary Sources List of Figures Figure 1. Repurposed Drugs Image Figure 2. Global Repurposed Drugs Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Repurposed Drugs Market Size Share 2021 VS 2025 VS 2032 Figure 4. Generic Drugs Image Figure 5. Clinical Trial Failed Drugs Image Figure 6. Global Repurposed Drugs Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Repurposed Drugs Market Size Share 2021 VS 2025 VS 2032 Figure 8. Cardiovascular Diseases Image Figure 9. Mental Illness Image Figure 10. Cancer Image Figure 11. Other Image Figure 12. Global Repurposed Drugs Market Size (US$ Million) & (2021-2032) Figure 13. Global Repurposed Drugs Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 14. Global Repurposed Drugs Market Share by Region: 2021 VS 2025 VS 2032 Figure 15. Global Repurposed Drugs Players Revenue Share Top 10 and Top 5 in 2025 Figure 16. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 17. Global Repurposed Drugs Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Repurposed Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 19. Global Repurposed Drugs Revenue Market Share by Type (2021-2032) Figure 20. Global Repurposed Drugs Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global Repurposed Drugs Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 22. Global Repurposed Drugs Revenue Market Share by Application (2021-2032) Figure 23. North America Repurposed Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 24. North America Repurposed Drugs Revenue Share by Type (2021-2032) Figure 25. North America Repurposed Drugs Revenue Share by Application (2021-2032) Figure 26. North America Repurposed Drugs Revenue Share by Country (2021-2032) Figure 27. United States Repurposed Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Canada Repurposed Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Mexico Repurposed Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Europe Repurposed Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 31. Europe Repurposed Drugs Revenue Share by Type (2021-2032) Figure 32. Europe Repurposed Drugs Revenue Share by Application (2021-2032) Figure 33. Europe Repurposed Drugs Revenue Share by Country (2021-2032) Figure 34. Germany Repurposed Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. France Repurposed Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. U.K. Repurposed Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Italy Repurposed Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Spain Repurposed Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Russia Repurposed Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Netherlands Repurposed Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Nordic Countries Repurposed Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. China Repurposed Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 43. China Repurposed Drugs Revenue Share by Type (2021-2032) Figure 44. China Repurposed Drugs Revenue Share by Application (2021-2032) Figure 45. Asia Repurposed Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 46. Asia Repurposed Drugs Revenue Share by Type (2021-2032) Figure 47. Asia Repurposed Drugs Revenue Share by Application (2021-2032) Figure 48. Asia Repurposed Drugs Revenue Share by Region (2021-2032) Figure 49. Japan Repurposed Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. South Korea Repurposed Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. India Repurposed Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Australia Repurposed Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Taiwan Repurposed Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Southeast Asia Repurposed Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. SAMEA Repurposed Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 56. SAMEA Repurposed Drugs Revenue Share by Type (2021-2032) Figure 57. SAMEA Repurposed Drugs Revenue Share by Application (2021-2032) Figure 58. SAMEA Repurposed Drugs Revenue Share by Country (2021-2032) Figure 59. Brazil Repurposed Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Argentina Repurposed Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Chile Repurposed Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Colombia Repurposed Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Peru Repurposed Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Saudi Arabia Repurposed Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Israel Repurposed Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. UAE Repurposed Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Turkey Repurposed Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Iran Repurposed Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Egypt Repurposed Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Years Considered Figure 71. Research Process Figure 72. Key Executives Interviewed

Scope & coverage.

Types
  • Generic Drugs
  • Clinical Trial Failed Drugs
Applications
  • Cardiovascular Diseases
  • Mental Illness
  • Cancer
  • Other
Companies covered
  • Teva
  • Johnson & Johnson
  • Novartis
  • Mylan
  • Pfizer
  • GSK
  • R-Pharma
  • Glenmark
  • Fujifilm
  • Dr. Reddy
  • ChemRar Group
  • Bausch Health

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Repurposed Drugs Market by Type
  3. 1.2.1 Global Repurposed Drugs Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Generic Drugs
  5. 1.2.3 Clinical Trial Failed Drugs
  6. 1.3 Repurposed Drugs Market by Application
  7. 1.3.1 Global Repurposed Drugs Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Cardiovascular Diseases
  9. 1.3.3 Mental Illness
  10. 1.3.4 Cancer
  11. 1.3.5 Other
  12. 1.4 Assumptions and Limitations
  13. 1.5 Study Goals and Objectives
2 Repurposed Drugs Market Dynamics
  1. 2.1 Repurposed Drugs Industry Trends
  2. 2.2 Repurposed Drugs Industry Drivers
  3. 2.3 Repurposed Drugs Industry Opportunities and Challenges
  4. 2.4 Repurposed Drugs Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Repurposed Drugs Market Perspective (2021-2032)
  2. 3.2 Global Repurposed Drugs Growth Trends by Region
  3. 3.2.1 Global Repurposed Drugs Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Repurposed Drugs Market Size by Region (2021-2026)
  5. 3.2.3 Global Repurposed Drugs Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Repurposed Drugs Revenue by Players
  2. 4.1.1 Global Repurposed Drugs Revenue by Players (2021-2026)
  3. 4.1.2 Global Repurposed Drugs Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Repurposed Drugs Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Repurposed Drugs Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Repurposed Drugs Key Players Headquarters & Area Served
  7. 4.4 Global Repurposed Drugs Players, Product Type & Application
  8. 4.5 Global Repurposed Drugs Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Repurposed Drugs Market CR5 and HHI
  11. 4.6.3 2025 Repurposed Drugs Tier 1, Tier 2, and Tier 3
5 Repurposed Drugs Market Size by Type
  1. 5.1 Global Repurposed Drugs Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Repurposed Drugs Revenue by Type (2021-2032)
  3. 5.3 Global Repurposed Drugs Revenue Market Share by Type (2021-2032)
6 Repurposed Drugs Market Size by Application
  1. 6.1 Global Repurposed Drugs Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Repurposed Drugs Revenue by Application (2021-2032)
  3. 6.3 Global Repurposed Drugs Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Teva
  2. 7.1.1 Teva Company Information
  3. 7.1.2 Teva Business Overview
  4. 7.1.3 Teva Repurposed Drugs Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Teva Repurposed Drugs Product Portfolio
  6. 7.1.5 Teva Recent Developments
  7. 7.2 Johnson & Johnson
  8. 7.2.1 Johnson & Johnson Company Information
  9. 7.2.2 Johnson & Johnson Business Overview
  10. 7.2.3 Johnson & Johnson Repurposed Drugs Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Johnson & Johnson Repurposed Drugs Product Portfolio
  12. 7.2.5 Johnson & Johnson Recent Developments
  13. 7.3 Novartis
  14. 7.3.1 Novartis Company Information
  15. 7.3.2 Novartis Business Overview
  16. 7.3.3 Novartis Repurposed Drugs Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Novartis Repurposed Drugs Product Portfolio
  18. 7.3.5 Novartis Recent Developments
  19. 7.4 Mylan
  20. 7.4.1 Mylan Company Information
  21. 7.4.2 Mylan Business Overview
  22. 7.4.3 Mylan Repurposed Drugs Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Mylan Repurposed Drugs Product Portfolio
  24. 7.4.5 Mylan Recent Developments
  25. 7.5 Pfizer
  26. 7.5.1 Pfizer Company Information
  27. 7.5.2 Pfizer Business Overview
  28. 7.5.3 Pfizer Repurposed Drugs Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Pfizer Repurposed Drugs Product Portfolio
  30. 7.5.5 Pfizer Recent Developments
  31. 7.6 GSK
  32. 7.6.1 GSK Company Information
  33. 7.6.2 GSK Business Overview
  34. 7.6.3 GSK Repurposed Drugs Revenue and Gross Margin (2021-2026)
  35. 7.6.4 GSK Repurposed Drugs Product Portfolio
  36. 7.6.5 GSK Recent Developments
  37. 7.7 R-Pharma
  38. 7.7.1 R-Pharma Company Information
  39. 7.7.2 R-Pharma Business Overview
  40. 7.7.3 R-Pharma Repurposed Drugs Revenue and Gross Margin (2021-2026)
  41. 7.7.4 R-Pharma Repurposed Drugs Product Portfolio
  42. 7.7.5 R-Pharma Recent Developments
  43. 7.8 Glenmark
  44. 7.8.1 Glenmark Company Information
  45. 7.8.2 Glenmark Business Overview
  46. 7.8.3 Glenmark Repurposed Drugs Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Glenmark Repurposed Drugs Product Portfolio
  48. 7.8.5 Glenmark Recent Developments
  49. 7.9 Fujifilm
  50. 7.9.1 Fujifilm Company Information
  51. 7.9.2 Fujifilm Business Overview
  52. 7.9.3 Fujifilm Repurposed Drugs Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Fujifilm Repurposed Drugs Product Portfolio
  54. 7.9.5 Fujifilm Recent Developments
  55. 7.10 Dr. Reddy
  56. 7.10.1 Dr. Reddy Company Information
  57. 7.10.2 Dr. Reddy Business Overview
  58. 7.10.3 Dr. Reddy Repurposed Drugs Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Dr. Reddy Repurposed Drugs Product Portfolio
  60. 7.10.5 Dr. Reddy Recent Developments
  61. 7.11 ChemRar Group
  62. 7.11.1 ChemRar Group Company Information
  63. 7.11.2 ChemRar Group Business Overview
  64. 7.11.3 ChemRar Group Repurposed Drugs Revenue and Gross Margin (2021-2026)
  65. 7.11.4 ChemRar Group Repurposed Drugs Product Portfolio
  66. 7.11.5 ChemRar Group Recent Developments
  67. 7.12 Bausch Health
  68. 7.12.1 Bausch Health Company Information
  69. 7.12.2 Bausch Health Business Overview
  70. 7.12.3 Bausch Health Repurposed Drugs Revenue and Gross Margin (2021-2026)
  71. 7.12.4 Bausch Health Repurposed Drugs Product Portfolio
  72. 7.12.5 Bausch Health Recent Developments
8 North America
  1. 8.1 North America Repurposed Drugs Revenue (2021-2032)
  2. 8.2 North America Repurposed Drugs Revenue by Type (2021-2032)
  3. 8.2.1 North America Repurposed Drugs Revenue by Type (2021-2026)
  4. 8.2.2 North America Repurposed Drugs Revenue by Type (2027-2032)
  5. 8.3 North America Repurposed Drugs Revenue Share by Type (2021-2032)
  6. 8.4 North America Repurposed Drugs Revenue by Application (2021-2032)
  7. 8.4.1 North America Repurposed Drugs Revenue by Application (2021-2026)
  8. 8.4.2 North America Repurposed Drugs Revenue by Application (2027-2032)
  9. 8.5 North America Repurposed Drugs Revenue Share by Application (2021-2032)
  10. 8.6 North America Repurposed Drugs Revenue by Country
  11. 8.6.1 North America Repurposed Drugs Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Repurposed Drugs Revenue by Country (2021-2026)
  13. 8.6.3 North America Repurposed Drugs Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
9 Europe
  1. 9.1 Europe Repurposed Drugs Revenue (2021-2032)
  2. 9.2 Europe Repurposed Drugs Revenue by Type (2021-2032)
  3. 9.2.1 Europe Repurposed Drugs Revenue by Type (2021-2026)
  4. 9.2.2 Europe Repurposed Drugs Revenue by Type (2027-2032)
  5. 9.3 Europe Repurposed Drugs Revenue Share by Type (2021-2032)
  6. 9.4 Europe Repurposed Drugs Revenue by Application (2021-2032)
  7. 9.4.1 Europe Repurposed Drugs Revenue by Application (2021-2026)
  8. 9.4.2 Europe Repurposed Drugs Revenue by Application (2027-2032)
  9. 9.5 Europe Repurposed Drugs Revenue Share by Application (2021-2032)
  10. 9.6 Europe Repurposed Drugs Revenue by Country
  11. 9.6.1 Europe Repurposed Drugs Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Repurposed Drugs Revenue by Country (2021-2026)
  13. 9.6.3 Europe Repurposed Drugs Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Netherlands
  19. 9.6.9 Nordic Countries
10 China
  1. 10.1 China Repurposed Drugs Revenue (2021-2032)
  2. 10.2 China Repurposed Drugs Revenue by Type (2021-2032)
  3. 10.2.1 China Repurposed Drugs Revenue by Type (2021-2026)
  4. 10.2.2 China Repurposed Drugs Revenue by Type (2027-2032)
  5. 10.3 China Repurposed Drugs Revenue Share by Type (2021-2032)
  6. 10.4 China Repurposed Drugs Revenue by Application (2021-2032)
  7. 10.4.1 China Repurposed Drugs Revenue by Application (2021-2026)
  8. 10.4.2 China Repurposed Drugs Revenue by Application (2027-2032)
  9. 10.5 China Repurposed Drugs Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Repurposed Drugs Revenue (2021-2032)
  2. 11.2 Asia Repurposed Drugs Revenue by Type (2021-2032)
  3. 11.2.1 Asia Repurposed Drugs Revenue by Type (2021-2026)
  4. 11.2.2 Asia Repurposed Drugs Revenue by Type (2027-2032)
  5. 11.3 Asia Repurposed Drugs Revenue Share by Type (2021-2032)
  6. 11.4 Asia Repurposed Drugs Revenue by Application (2021-2032)
  7. 11.4.1 Asia Repurposed Drugs Revenue by Application (2021-2026)
  8. 11.4.2 Asia Repurposed Drugs Revenue by Application (2027-2032)
  9. 11.5 Asia Repurposed Drugs Revenue Share by Application (2021-2032)
  10. 11.6 Asia Repurposed Drugs Revenue by Country
  11. 11.6.1 Asia Repurposed Drugs Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Repurposed Drugs Revenue by Country (2021-2026)
  13. 11.6.3 Asia Repurposed Drugs Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Repurposed Drugs Revenue (2021-2032)
  2. 12.2 SAMEA Repurposed Drugs Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Repurposed Drugs Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Repurposed Drugs Revenue by Type (2027-2032)
  5. 12.3 SAMEA Repurposed Drugs Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Repurposed Drugs Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Repurposed Drugs Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Repurposed Drugs Revenue by Application (2027-2032)
  9. 12.5 SAMEA Repurposed Drugs Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Repurposed Drugs Revenue by Country
  11. 12.6.1 SAMEA Repurposed Drugs Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Repurposed Drugs Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Repurposed Drugs Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst